High Prevalence of Celiac Disease Among Screened First-Degree Relatives.


Journal

Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543

Informations de publication

Date de publication:
09 2019
Historique:
received: 07 12 2018
revised: 24 02 2019
accepted: 04 03 2019
pubmed: 27 8 2019
medline: 14 1 2020
entrez: 27 8 2019
Statut: ppublish

Résumé

To investigate the prevalence of first-degree relatives (FDRs) with celiac disease detected at screening and diagnostic significance of anti-tissue transglutaminase (anti-TTG). We performed a retrospective cohort study of 104 patients with a diagnosis of celiac disease and their FDRs, collecting data from electronic records of Mayo Clinic and celiac disease registry from December 20, 1983, to May 22, 2017. We collected demographics, presenting symptoms, indication for testing, family history, number of other family members screened, biopsy reports, and results of serologic tests. Of 477 FDRs identified, 360 were screened (mean screening rate per family, 79%±25%) and 160 FDRs (44.4%) were diagnosed with celiac disease, at a mean age 31.9±21.6 years (62% female). All diagnosed FDRs had positive anti-TTG titers. Clinical features were documented in 148 diagnosed FDRs, of those 9 (6%) had classic, 97 (66%) had non-classic symptoms, and 42(28%) had no reported symptoms. Histology reports were available from 155 FDRs: 12 (8%) had Marsh 1, 77 (50%) had Marsh 3a, and 66 (43%) had Marsh 3b. A level of anti-TTG greater than or equal to 2.75 of the upper limit of normal identified FDRs with villous atrophy with 87% sensitivity, 82% specificity, and a positive predictive value of 95%. In a retrospective cohort study of patients diagnosed with celiac disease, we found a high prevalence of celiac disease among screened FDRs. High anti-TTG titers associated with villous atrophy on small bowel biopsies, irrespective of symptoms.

Identifiants

pubmed: 31447136
pii: S0025-6196(19)30353-2
doi: 10.1016/j.mayocp.2019.03.027
pii:
doi:

Substances chimiques

Protein Glutamine gamma Glutamyltransferase 2 EC 2.3.2.13
Transglutaminases EC 2.3.2.13
GTP-Binding Proteins EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1807-1813

Informations de copyright

Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Shilpa S Nellikkal (SS)

Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Yamen Hafed (Y)

Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Joseph J Larson (JJ)

Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.

Joseph A Murray (JA)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Imad Absah (I)

Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: absah.imad@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH